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Commentary
In a lecture at the “Genomics in Cancer Risk 
Assessment” workshop in 2009, Hans Lehrach 
of the Max Planck Institute for Molecular 
Genetics stated that, “Life is the translation of 
the information in the genome into the pheno­
type of the organism. The organism ‘computes’ 
this phenotype from its genotype, given a spe­
cific environment.” The goal of human risk 
assessment is to decide whether a given level of 
exposure to a particular chemical or substance 
is acceptable to human health and to provide 
risk management measures based on an evalua­
tion and prediction of the effects of that expo­
sure on human health. Within this framework, 
the current safety paradigm for assessing pos­
sible carcinogenic properties of drugs, cosmet­
ics, industrial chemicals, and environmental 
exposures relies mainly on in vitro genotoxicity 
testing followed by 2­year bioassays in mice 
and rats. This testing paradigm was developed 
40–50 years ago with the initial premise that 
“mutagens are also carcinogens” (Ames 1973) 
and that the carcinogenic risk to humans can 
be extrapolated from the tumor incidence in 
rodents after lifetime exposure to maximally tol­
erated doses of chemicals  (Weisburger 1983).
Genotoxicity testing is used as a surro­
gate for carcinogenicity testing and is required 
for initiation of clinical trials (Jacobs and 
Jacobson­Kram 2004) and for most safety 
assessments of industrial chemicals. Although 
the carcinogenicity­testing paradigm has 
effectively protected patients and consumers 
from the introduction of harmful carcinogens 
as drugs and other products, the testing para­
digm is clearly not sustainable in the future. 
The causal link between genetic damage and 
carcinogenicity is well documented; however, 
the limitations of genotoxicity and carcinoge­
nicity testing assays, the presence of additional 
nongenotoxic mechanisms, issues of species­
specific effects, and the lack of mechanistic 
insights provide enormous scientific challenges.
The genetic toxicology testing battery 
has been designed to be highly sensitive in 
predicting chemical carcinogenicity. The 
genetic toxicology testing battery detects 
93% of carcinogens (Kirkland et al. 2005, 
2006). However, the extremely high sensitiv­
ity of the testing paradigm comes at a cost 
of very low specificity. For instance, 50% 
of noncarcinogens among pharmaceuticals 
have some findings in genotoxicity assays 
(Hoffmann and Hartung 2006; MacDonald 
2004; Snyder 2009; Snyder and Green 2001). 
Furthermore, the current testing paradigm 
for carcinogenicity fails to detect a variety of 
nongenotoxic carcinogens, such as hormone­
type agents, which may impose a considerable 
human health risk.
The 2­year rodent carcinogenicity bio­
assays are associated with high costs, high 
animal burden, a long time frame (often 
≥ 3 years), limited accuracy, and the uncer­
tainty associated with extrapolating from 
rodents to humans. Additional frustrations 
exist because of the limited predictability of 
the 2­year bioassay and, in particular, the 
problem of predicting false positives. For 
instance, the Carcinogenic Potency Database 
(Gold 2010) includes results from chronic, 
long­term animal cancer tests with mice, rats, 
and hamsters amounting to a total of 6,540 
individual experiments with 1,547 chemicals; 
751 of those chemicals (51%) have positive 
findings in rodent studies. Similarly, when one 
considers all chronically used human pharma­
ceuticals, some 50% induce tumors in rodents, 
yet only 20 human pharmaceutical com­
pounds have been identified as carcinogens in 
epidemiological studies, despite the fact that 
quite a large number of epidemiological stud­
ies have been carried out on these compounds 
(e.g., nonsteroidal antiinflammatory drugs, 
benzodiazepines, and phenobarbital). This 
high incidence of tumors in bioassays has led 
to questions concerning the human relevance 
of tumors induced in rodents (Knight et al. 
2006; Ward 2008).
In addition, concerns have been raised 
regarding the age­related tumor incidence in 
the rodent bioassay, with many tumors arising 
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only after 18–24 months of exposure. In 
contrast, most compounds designated by the 
International Agency for Research on Cancer 
(2010) to be human carcinogens induce 
tumors in rodents within 12 months of expo­
sures (with some exceptions of tumors not 
arising until up to 18 months). A growing 
body of evidence indicates that rodent tumors 
(particularly from nongenotoxic chemicals) 
result from alternative or secondary mecha­
nisms that are unique to rodents and therefore 
are not necessarily predictive of human hazard. 
Therefore, the dilemma remains as to the rele­
vance of rodent bioassay findings to human 
mechanisms of carcinogenicity and human 
cancer risk.
In summary, dependency on the rodent 
model as a gold standard of cancer risk 
assessment neglects the high number of false 
positives and clearly has serious limitations. 
Consequently, there is a growing appeal for 
a paradigm change after “50 years of rats and 
mice.” Recent reports from the National 
Research Council of the U.S. National 
Academies have focused on the challenges of 
toxicology and human risk assessment, appeal­
ing for dramatic changes to move forward 
(National Research Council 2007a, 2007b). 
In addition, the current demands for toxicity 
and carcinogenicity testing of high­volume 
chemicals together with limitations of animal 
use as stipulated by the European Union’s 
Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) regu­
lation (Combes et al. 2006) will require 
revolutionary changes in testing and risk 
assessment   paradigms.
To develop a road map for this needed 
paradigm change in carcinogenicity test­
ing, a workshop was held in August 2009 in 
Venice, Italy, titled “Genomics in Cancer Risk 
Assessment.” This workshop brought together 
toxicologists from academia and industry and 
government regulators and risk assessors from 
the United States and the European Union to 
discuss the state­of­the­art in developing alter­
native testing strategies for carcino  genicity, 
focusing on contributions from the omics 
technologies. What follows is a highlight of 
the major conclusions and suggestions from 
this workshop as a path forward.
The Challenge: Addressing 
Human Relevance
Participants concluded, based on both scientific 
and technical reasons, that the current assays 
need to be improved if not replaced by 
mechanism­based assays that would enable 
assessment of relevance of observed findings 
for human health and disease. Preferentially, 
these assays should be derived from human 
in vitro cellular models and should be properly 
validated against human in vivo data (com­
ing from investigations of patients, clinical 
trials, and human biomarker research) through 
translational research. New assays optimally 
should not rely on animal use and should 
have sufficient throughput that would satisfy 
demands for testing. Despite an array of cur­
rently established in vitro and in vivo testing 
methods, deriving insights into carcinogenic 
mechanisms with respect to the oncogenic 
potential of chemicals to humans is a difficult 
task. One suggestion to improve human can­
cer risk assessment is to incorporate genomic 
and genetic approaches into the risk assess­
ment paradigm (Ellinger­Ziegelbauer et al. 
2008a; Guyton et al. 2008). Because molecular 
or informational pathways are generally con­
served across species from yeast to man (Ideker 
et al. 2001) and because pathways are gener­
ally well represented on all assay platforms, 
although the actual representation may vary, 
genomic­based systems biology approaches 
have the potential to bridge the in vitro and 
in vivo preclinical assays with human­relevant 
cancer mechanisms. Where pathways differ 
between species, those differences can provide 
valuable insight in understanding molecular 
mechanisms responsible for species­specific 
responses to exposures. Remarkable research 
activity is being conducted in the use of 
genomics as a tool for toxicological evaluation 
of chemicals and pharmaceuticals, including 
genotoxic and nongenotoxic carcinogenicity 
investigations after both in vitro and in vivo 
exposures. Several successful demonstrations 
of limited and well­defined applications of 
genomic approaches to risk assessment 
have included the identification of hazards 
through classification of test or unknown 
compounds with compounds of a particular 
class (Hamadeh et al. 2002; van Delft et al. 
2004), the generation of mechanistic infor­
mation through molecular pathway analysis 
revealing biological processes effected by expo­
sures (Amundson et al. 2005; Aubrecht and 
Caba 2005; Heinloth et al. 2003; Liu et al. 
2006), and the prediction of a limited num­
ber of specific potential adverse effects from 
exposures (Ellinger­Ziegelbauer et al. 2005, 
2008b; Fielden et al. 2007; Heinloth et al. 
2004; van Delft et al. 2004).
Recent work by Lamb and colleagues 
integrates gene expression transcriptomics 
data from human cells with chemical and 
drug information together with disease 
information into what the authors refer to as 
a “Connectivity Map” (Lamb 2007; Lamb 
et al. 2006). Applying this approach to sys­
tems biology, the authors demonstrate their 
ability to discover the activity of a compound 
(referred to as a “perturbagen”) in a molecu­
lar pathway that the compound had not pre­
viously been known to affect. Although this 
data set was clearly limited, the results were 
promising. The implication of this study is 
that a more robust database of information 
might provide insight into potential risks rele­
vant to human exposures to a wide variety of 
chemicals and drugs.
For nongenotoxic chemicals, the impor­
tant signals for identifying human cancer haz­
ards may be detected in shorter­term studies 
using toxicogenomics approaches, rather than 
routinely relying on data from 2­year rodent 
bioassays. Characteristic pathway­associated 
gene expression signatures have been identi­
fied in the liver and kidneys of rats after short­
term (2 weeks or 90 days) treatment with 
carcinogens, which fit very well the known 
mechanisms of carcinogenesis (Auerbach et al. 
2010). These can discriminate genotoxic and 
nongenotoxic carcinogens from noncarcino­
gens, with a typical sensitivity of 0.92 and 
specificity of 0.88, a significant improvement 
over the performance of current animal­based 
models. This may contribute to weight­of­
evidence considerations in cancer risk assess­
ment. Pathway­associated gene signatures 
may serve as biomarkers that may then help 
to predict a carcinogenic hazard in differ­
ent organs even after short­term treatment 
(Ellinger­Ziegelbauer et al. 2008a).
Perhaps the ideal approach for assess­
ing human risk associated with exposure to 
chemical carcinogens would be an in vitro 
assay that would apply genomics in con­
junction with bioinformatics methods to 
interrogate mechanisms of action of tested 
compounds. This information would then 
be used for the development and qualifica­
tion of genomic biomarkers for chemical 
carcinogenesis that would provide the basis 
for mechanism­based risk assessment. In vitro 
classification of compounds for true genotoxic 
and nongenotoxic carcinogenicity, using cell 
lines, including human liver cellular mod­
els, can be 70–90% accurate (van Delft et al. 
2004). Furthermore, developing a genomic­
based biomarker approach to identify irrel­
evant findings, for instance, findings from 
in vitro chromosome damage assays that 
are false positives and irrelevant findings 
for human risk assessment, would have spe­
cific, immediate human relevance and would 
provide significant improvement in current 
genotoxicity testing (Aubrecht and Caba 
2005; Goodsaid et al. 2010). Tissue­specific 
in vitro approaches to recognize carcinogens 
need to be developed, and such efforts would 
focus research appropriately on producing 
necessary tools to address organ specific­
ity and ultimately improve prediction and 
risk assessment (carcinoGENOMICS 2007; 
Vinken et al. 2008). Furthermore, high­
  throughput approaches that are currently 
being evaluated by the U.S. Environmental 
Protection Agency (EPA) ToxCast effort and 
by the National Institute of Environmental 
Health Sciences, National Toxicology 
Program, the National Human Genome Genomics and human cancer risk assessment
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Research Institute, and the U.S. EPA Tox21 
high­throughput screening effort have con­
centrated on a functional genomic approach 
that would allow triage of compounds for 
testing. These efforts could thus provide the 
opportunity to focus limited resources on 
the most important, problematic compounds 
(Dix et al. 2007).
Gaps to Be Addressed
The ultimate, long­term goal for applying 
genomic­based approaches to human cancer 
risk assessment is the eventual replacement of 
the current testing paradigm, which includes 
genotoxicity and carcinogenicity testing, with 
mechanism­based assays that would allow 
both hazard detection and assessment of the 
relevance to humans, not rodents, of observed 
findings. For this to become a reality, molecu­
lar alterations and mechanistic insight derived 
from human cellular models need to be 
correlated with injury or potential for injury in 
humans. Linking outcomes of toxico  genomics 
investigations in vitro to ongoing human 
omics­based biomarker studies could help 
to make this happen. Consequently, more 
extensive data that are derived from human 
studies are needed, in particular, appropriate 
samples from individuals exposed at low but 
well­  defined levels. Because development of 
biomarkers suitable to monitor exposure in 
human populations is essential to human risk 
and relevance, approaches to develop genomic 
biomarkers for individuals exposed to a specific 
agent of concern would provide the necessary 
advances to develop broad biomarker­based 
approaches (McHale et al. 2010). Genomic 
approaches have the potential to facilitate the 
discovery of surrogate biomarkers that are 
gene expression signatures or expression pat­
terns of proteins or metabolites linked with 
a particular phenotype. This “phenotypic 
anchoring” of genomic signatures (Paules 
2003) would allow for the use of patterns as 
surrogate biomarkers that may be useful in 
treatment and risk assessment decision making 
in the clinical or regulatory setting, even if the 
underlying molecular mechanism is not fully 
understood. This approach has been demon­
strated powerfully with gene­expression–based 
surrogate biomarkers that have provided infor­
mation to clinicians about the prognosis of 
breast tumors and that have helped in the 
design of appropriate therapeutic treatment 
regimes (Paik et al. 2004; Sotiriou and Pusztai 
2009; van ’t Veer et al. 2002). Thus, genomic 
approaches that use appropriate human sam­
ples from well­designed studies of exposed 
human populations may yield powerful novel 
biomarkers useful both in the clinical setting 
and in risk assessment.
Systems toxicology approaches should 
also pay attention to the relative sensitivity 
of humans and the variability in the human 
response. As carcinogens are increasingly 
recognized to affect multiple molecular 
mechanisms and thus multiple cellular path­
ways, insights into these mechanisms could 
inform new predictive approaches, such as 
predictive in vitro assays, and allow for the 
development of specific, mechanism­based 
human biomarkers. These new biomarkers 
could then provide insight into the genetic 
variability in responses to the risk of develop­
ing cancers. The use of such mechanistic data 
will play a key role in the future of risk assess­
ment to aid in identification of additional 
sources of human variability and susceptibility 
(e.g., background diseases and processes, coex­
posures) and improve prediction of interac­
tions across environmental and endogenous 
exposures. Identifying mechanistic drivers of 
adverse responses will be particularly impor­
tant in the risk assessment of exposures at low 
doses. Once progress is made in these areas, it 
may be possible to address the dose–response 
curve in an individual, which can take mul­
tiple forms, depending on such factors as the 
individual’s genetic background, the target 
tissue affected, and the actual internal dose 
of a specific compound or chemical. Linking 
outcomes of in vitro toxicogenomics inves­
tigations to ongoing human omics­based 
biomarker studies may make this happen. 
Goodsaid et al (2010) noted that regulators 
appear to be willing to accept such approaches 
where use is clearly defined, evidence is strong, 
and approaches are validated and qualified for 
regulatory use. In general, educating stake­
holders is crucial to successfully implement the 
new testing paradigm.
Toxicogenomics applications require 
further technological standardization as 
well as biological standardization, especially 
with respect to the annotation of genes and 
pathways related to toxicologically rele­
vant end points. Further progress must be 
made in systems toxicology applications, 
Figure 1. Road map for human cancer risk assessment. Four major projects that aim to develop a genomic 
biomarker approach for human cancer risk assessment have been initiated in the United States and the 
European Union (EU). carcinoGENOMICS (EU’s Sixth Framework Programme, funded from 2009 to 2012) 
attempts to develop human cell-based in vitro models and tools to detect carcinogens. The Phase I and 
the Phase II studies, conducted by the U.S. EPA (ToxCast program) and the National Institutes of Health 
(Tox21 program), exploit available biochemical and molecular assays to develop high-throughput, predic-
tive assay panels. The International Life Sciences Institute Health and Environmental Sciences Institute 
(ILSI HESI) Genotoxicity Working Group (Genotox WG) focuses on developing an in vitro genomic biomark-
ers that can provide mechanistic context to in vitro genotoxicity testing. The aim of the FDA’s Critical Path 
Initiative Predictive Safety Testing Consortium Carcinogenicity Working Group (PSTC Carcinogenicity WG) 
is to develop an in vivo genomic biomarker detecting hepatocarcinogenicity, applicable for use in early 
drug development. These initiatives are expected to yield biomarkers and assays that initially could be 
applied as weight of evidence in a fit-for-purpose manner. This will provide the time and opportunity for 
refining the methods and assembling a new testing paradigm. Concurrently, progress in the development 
of cancer diagnostic methods is expected to provide data specific to human cancer that, after integra-
tion with in vitro and preclinical genomics data, will open additional avenues to further increase human 
relevance of this new testing paradigm. Solid lines indicate current funding activities; dotted lines indicate 
anticipated continuation of funding or projects into the future.
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that is, developing integrative approaches 
across multiple genomic, genetic, molecu­
lar, and cellular assays to assess toxic events 
from a holistic perspective, as described 
with the Connectivity Map approach. The 
first generation toxicogenomics studies used 
microarray­based whole­genome analysis of 
gene expression modifications. Current tech­
nologies analyze the interplay between epi­
genetic events (e.g., whole­genome DNA 
methylation and histone acetylation, modifica­
tions of levels of mRNA, modifications of lev­
els of regulatory microRNAs) and proteomic 
and metabolomic events, thus increasing 
the potential of identifying pivotal pathways 
whose perturbation functionally contributes 
ultimately in inducing toxicity and disease. 
To accomplish this will require better data 
analysis tools, specifically bioinformatics­based 
decision­supporting tools, to help not only 
the research scientists but also chemical and 
drug registrants and regulators. Furthermore, 
this will require publically accessible databases 
that integrate different methods and types 
of information, from emerging omics data 
types to traditional pathological, toxicologi­
cal, physiological, molecular, and clinical data. 
New methods of training and familiarizing all 
parties involved with these new tools and strat­
egies will be needed. This training may require 
new additions to existing curricula for students 
and special, targeted training   opportunities 
for professionals.
A major challenge is the need to pheno­
typically anchor genomic responses from 
in vitro studies and testing assays on chemical 
carcinogenesis to human patho  physiology. 
The critical need for human relevancy is not 
a new problem but a serious issue that has 
appeared to be intractable in the past, because 
of, at least in part, the paucity of critical 
human samples and information. For this 
to be overcome now, cooperation and data 
sharing between private and public research 
partners and broad collaborative efforts will 
be required.
The Path Forward
Toxicogenomics is considered a very promis­
ing but complex technology requiring coor­
dinated planning and execution that is highly 
transparent and participatory to all segments 
of toxicology and risk assessment: academia, 
government, industry, non  governmental orga­
nizations, and the public. Although we are still 
far from replacing the current testing para­
digm for cancer risk assessment, toxicogenom­
ics approaches at their current stage may be 
used to add weight of evidence to a risk assess­
ment, by supporting additional studies in the 
presence or absence of a certain mechanism 
or mode of action and by describing end 
points that are not evaluated in a “checklist” 
manner but through an integrated scientific 
approach. Much work is needed, but a num­
ber of activities both in Europe and in the 
United States are already ongoing that will 
help address the issue of bringing genomic 
approaches into human cancer risk assess­
ment (Figure 1). In support of this approach, 
the U.S. Food and Drug Administration in a 
joint undertaking with the European Union’s 
European Medicines Agency has already 
invited the pharmaceutical industry to submit 
omics data in the context of the registration 
of novel compounds (Goodsaid et al. 2010). 
Importantly, the REACH legislation states:
The Commission, Member States, industry and 
other stakeholders should continue to contribute 
to the promotion of alternative test methods on an 
international and national level including computer 
supported methodologies, in vitro methodologies, 
as appropriate, those based on toxicogenomics, and 
other relevant methodologies. (REACH Online 
2006)
Regulatory agencies should not simply wait for 
these future developments but should antici­
pate that these novel toxicogenomics­based 
approaches also require the development of 
novel quality standards and further regula­
tory criteria. We feel it is critical to establish 
a formal global dialogue among regulatory 
agencies to coordinate and facilitate prog­
ress and acceptance of anticipated advances 
(Figure 1, Regulatory discussions, Phase 
I and II). In this line, we call upon inter­
national regulatory agencies and risk assess­
ment decision makers to establish two phases 
of regu  lar dialogues, each over a 2­ or 3­year 
period, that will address initially the imple­
mentation of genomics­based assay develop­
ment and then the use of   genomics­based 
weight­of­evidence information in risk assess­
ment decisions. With the progress being made 
in science today using genomics approaches, 
particularly using readily accessible human 
material, in conjunction with rigorous tradi­
tional scientific endeavors, we are now at a 
point when genomic applications in human 
studies can yield important information for 
better human cancer risk assessment.
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